readthroughSign in
CompanySPRBNasdaqSouth San Francisco, CA

Spruce Biosciences

Spruce Biosciences develops tralesinidase alfa, an enzyme replacement therapy in late-stage development for mucopolysaccharidosis type IIIB (Sanfilippo Syndrome Type B), a pediatric neurodegenerative disorder.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 9Latest story